Sanofi-aventis and Regeneron Extend Therapeutic Antibody Agreement
By Taskin Ahmed
Pharma Deals Review: Vol 2009 Issue 11 (Table of Contents)
Published: 18 Nov-2009
DOI: 10.3833/pdr.v2009.i11.1274 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Sanofi-aventis has extended its November 2007 antibody venture with Regeneron Pharmaceuticals by increasing its annual funding from US$100 M to US$160 M to continue collaboration pact for discovery research until end of 2017...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS